WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Osteoporosis Efficacy Criteria v16, The proportion of patients with new fracture has outcome assessment Non-vertebral fracture, Quantitative Morphometry assesses Decrease in vertebral height, Bone Mineral Density (BMD) measured at Time points defined by protocol, FDA Efficacy Criteria for Osteoporosis additional variables for efficacy consideration Concomitant Medications that affect bone, Bone Mineral Density (BMD) measured in secondarily 1/3 distal radius, Blood for - Bone specific alkaline phosphatase(BSAP) - Serum Osteocalcin (OC) - P1NP - P1CP - Serum NTX, Observation or Assessment is used to monitor the effectiveness of Therapeutic Intervention, - Pyridinolines - CTX - NTX - Deoxypyridinoline (DPD) to determine bone resorption, Etiology of fracture instnatiated by - No trauma - Low trauma, Radiographic Report include Etiology of fracture, Decrease in vertebral height assessed as Relative % change from baseline, Absolute change derived from Vertebral height measurement, Patient's Medical History includes Patient's Medical History Details, Therapeutic Efficacy Endpoint is the intersection of Observation or Assessment, Semi-Quantitative Assessment measured for vertebrae T4 - L5, Non-vertebral fracture is confirmed by Radiographic Test, Area measured in cm^2, Urine for - Pyridinolines - CTX - NTX - Deoxypyridinoline (DPD), Decrease in vertebral height assessed as Absolute change, The proportion of patients with new fracture has outcome assessment Vertebral fracture (morphometric / clinical)